Precision Therapy Targeting FZD7 Shows Promise in Stopping Aggressive Breast Cancer
A groundbreaking new therapy developed by researchers at the University of California San Diego School of Medicine offers a potential breakthrough in the fight against triple-negative breast cancer (TNBC), a particularly aggressive and challenging form of the disease. The innovative approach utilizes an antibody-drug conjugate to deliver a potent chemotherapy directly to cancer cells, minimizing harm to healthy tissue and offering hope for patients who have limited treatment options.
Understanding the Challenge of Triple-Negative Breast Cancer
In 2025, an estimated 316,950 women and 2,800 men are projected to receive a diagnosis of invasive breast cancer. Within this landscape, TNBC represents a significant hurdle, accounting for 10–15% of all cases. Unlike other breast cancer subtypes, TNBC often resists hormonal therapies and tends to grow and spread more rapidly, leading to lower survival rates. This aggressive nature disproportionately impacts younger women, Black women, and individuals with specific genetic predispositions.
A Novel Approach: Antibody-Drug Conjugates and FZD7
The research, published in the Proceedings of the National Academy of Sciences, centers on an antibody-drug conjugate – a sophisticated delivery system. This technology employs an antibody to pinpoint cancer cells and then release a highly potent chemotherapy agent directly into those cells, sparing surrounding healthy tissue. This allows for the use of drugs that would otherwise be too toxic for systemic administration, opening new avenues for treating difficult-to-treat cancers.
Central to this new therapy is the identification of a cell-surface protein called FZD7. Researchers discovered that FZD7 is prominently present on cells exhibiting high tumor-initiating potential in TNBC. By engineering an antibody-drug conjugate specifically to target cells with FZD7, they achieved significant reductions in tumor growth in mouse models without observing any noticeable toxicity.
“We’ve identified a key marker on these aggressive cancer cells, allowing us to deliver a targeted blow,” stated a senior researcher involved in the study.
Further investigation using mouse-derived organoids – three-dimensional models of organ tissue – revealed that cells with FZD7 were not only more aggressive but also more susceptible to the treatment compared to other tumor cells. Importantly, the approach also demonstrated effectiveness in human TNBC cell lines.
Implications for Future Treatment
While further research is necessary to translate these findings into clinical applications, the study’s results suggest that targeting tumor-initiating cells through FZD7 could represent a paradigm shift for patients battling aggressive breast cancers that are unresponsive to existing therapies. The research team envisions this strategy paving the way for more precise and effective treatments for TNBC, and potentially extending to other cancers with similar biological characteristics.
The study was spearheaded by Dennis A. Carson, M.D., professor in the Department of Medicine, and Karl Willert, Ph.D., professor in the Department of Cellular & Molecular Medicine, both at UC San Diego School of Medicine.
More information about the research can be found in the publication: Christina C. N. Wu et al, FZD7 expression marks mammary tumor–initiating cells, Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.2522465122.
This innovative approach offers a beacon of hope in the ongoing quest to overcome the challenges posed by triple-negative breast cancer and improve outcomes for patients facing this devastating disease.
